Friday, 16 October 2026European Markets

GRAINES VOLTZ Stock Drops By 34% In The Last 21 Sessions

Loading stream...

(vianews) - shares of graines voltz (cac 40: grvo.pa) fell by a staggering 34.94% in 21 sessions from €65.4 to €42.55 at 15:06 est on tuesday, following the last session's upward trend. cac 40 is jumping 0.58% to €7,388.70, after five sequential sessions in a row of gains.

about graines voltz

graines voltz s.a. engages in the distribution of vegetable and flower seeds, seedlings, and bulbs in france and internationally. it also produces nursery plants. it serves professionals, horticulturists, market gardeners, nurseries, and local authorities. the company was incorporated in 1985 and is headquartered in colmar, france.

earnings per share

as for profitability, graines voltz has a trailing twelve months eps of €3.26.

pe ratio

graines voltz has a trailing twelve months price to earnings ratio of 13.06. meaning, the purchaser of the share is investing €13.06 for every euro of annual earnings.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, graines voltz's stock is considered to be overbought (>=80).

volatility

graines voltz's last week, last month's, and last quarter's current intraday variation average was a negative 6.39%, a negative 2.69%, and a positive 2.06%.

graines voltz's highest amplitude of average volatility was 6.57% (last week), 3.38% (last month), and 2.06% (last quarter).

volume

today's last reported volume for graines voltz is 1519 which is 19.02% below its average volume of 1246.

more news about graines voltz (grvo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com